Home
Live Updates
Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer : vimarsana.com
Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
/PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products...
Related Keywords
Yang Shi ,
Hunan ,
China ,
Taiwan ,
Shanghai ,
Hong Kong ,
Singapore ,
Hong Kong Special Administrative Region ,
Hong Kong General ,
South Korea ,
Chinese ,
Asia Pacific ,
Cancer Association ,
Department Of Health ,
Gilead Sciences Inc ,
Everest Medicines ,
New Drug Application ,
Chief Medical Officer ,
Greater China ,
Triple Negative Breast Cancer ,
Sacituzumab Govitecan ,
Gilead Sciences ,
Southeast Asian ,
Standardized Diagnosis ,
Advanced Breast Cancer ,
Breast Cancer Expert Committee ,
National Cancer Control Center ,
Breast Cancer Professional Committee ,
Chinese Anti Cancer Association ,
Chinese Anti Cancer ,
vimarsana.com © 2020. All Rights Reserved.